The global cold, allergy, and sinus tablet market are projected to grow at a significant CAGR during the forecast period (2022-2028). Some factors such as the increase in demand for pharmaceuticals (OTC), the increase in air pollution, as well as the increase in R&D spending on medicines, is driving the market growth. In addition, the market is growing due to the increase in asthma patients and the growing number of older people. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness due to inflammation and constriction of the tiny airways in the lungs. In 2019, asthma afflicted an estimated 262 million individuals, resulting in 461000 fatalities.
Browse the full report description of “Global Cold, Allergy, and Sinus Tablet Market Size Share and Trend Analysis Report, By Type (Cold Tablet, Allergy Tablet, and Sinus Tablet), By Distribution Channel (Hospitals Pharmacies, Drug & Medical stores, Online Store) Forecast Period, 2022-2028” at https://www.omrglobal.com/industry-reports/cold-allergy-and-sinus-tablet-market
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in July 2019 Dr. Reddy’s Laboratories Ltd. introduced its Allegra pills, a drug used to relieve symptoms of the common cold, flu, or allergies, in the US. The company can now sell the standard type of tablet as it has received US approval. For this, the company will sell “Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP, over-the-counter (OTC) brand-brand such as Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets.
In addition, North America is expected to have a significant market share due to the presence of well-established pharmaceutical products with a strong image. In addition, the market is growing due to FDA approval. For instance,, in March 2021, Merck announced the approval of a new drug application (NDA) for gefapixant from the US Food and Drug Administration (FDA). An oral, selective P2X3 receptor antagonist, is selected for the treatment of chronic cough (RCC) or unexplained chronic cough (UCC) in adults.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- including Merck & Co., Inc., GC Aesthetics, Allergan, Inc., Guangzhou Wanhe Plastics Materials Co. Ltd, Koken Co. Ltd., among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Cold, Allergy, and Sinus Tablet Market Report Segment
By Type
By Distribution Channel
Global Cold, Allergy, and Sinus Tablet Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/cold-allergy-and-sinus-tablet-market